Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2016-11-02 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Appendix 3B, 708A Notice & Listing Rule 3.10.5A information 14 pages 364.4KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. It includes detailed information about the class and number of securities issued, issue price, purpose, shareholder approvals, and quotation agreements. The document does not contain financial statements or management discussion but is focused on capital raising and securities issuance. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. The document length is substantial and contains detailed issuance data, confirming it is not a mere announcement of a report but a substantive filing about capital changes.
2016-11-02 English
AGM Presentation 12 pages 1.5MB
AGM Information Classification · 95% confidence The document is a detailed presentation by Imugene Limited, dated November 2, 2016, delivered by the Chief Operating Officer at an Annual General Meeting (AGM). It includes company overview, pipeline details, clinical trial information, leadership bios, and future news flow. The content is structured as a slide presentation with forward-looking statements, product descriptions, and strategic updates. There are no financial statements or audit information, nor is it a transcript of a call or a regulatory filing. The presence of the COO presenting at an AGM and the nature of the content strongly indicate this is an investor presentation made at the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2016-11-01 English
Results of Meeting 1 page 70.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'RESULTS OF ANNUAL GENERAL MEETING' and provides detailed voting results for resolutions considered at the AGM of Imugene Limited. It includes vote counts for each resolution, mentions the Corporations Act and Listing Rule compliance, and is signed by the Company Secretary. The content is a formal announcement of the voting outcomes at the AGM, not the AGM presentation materials themselves or the full annual report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused solely on voting results, confirming it is not a full report or presentation.
2016-11-01 English
Becoming a substantial holder 3 pages 144.4KB
Regulatory Filings
2016-10-30 English
Director Resignation - Final Director Interest Notice 3 pages 424.4KB
Board/Management Information Classification · 100% confidence The document announces the resignation of a director, Dr Anton Uvarov, from Imugene Limited and includes an Appendix 3Z Final Director's Interest Notice, which is a regulatory form related to director's shareholdings and interests. The content focuses on management changes and director interests rather than financial results or reports. The document length is short (3339 characters) and it is clearly an announcement of a director resignation and related disclosures. Therefore, it fits best under Board/Management Information (MANG).
2016-10-30 English
Appendix 3B 12 pages 286.2KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, application for quotation of additional securities, and agreement. It contains detailed information about the class, number, terms, issue price, purpose of the securities issued, shareholder approvals, and quotation agreements. The document references ASX (Australian Securities Exchange) rules and compliance requirements for issuing and quoting securities. It is a regulatory announcement about capital raising and securities issuance rather than a financial report or earnings release. The content aligns with updates on company fundraising and capital structure changes. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP). The document length is substantial and contains detailed information, not just a brief announcement or notice, supporting this classification with high confidence.
2016-10-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.